Antares Pharma, Inc. (ATRS)

NASDAQ: ATRS · IEX Real-Time Price · USD
5.59
0.01 (0.18%)
May 20, 2022 4:00 PM EDT - Market closed
Market Cap955.06M
Revenue (ttm)183.46M
Net Income (ttm)40.18M
Shares Out170.85M
EPS (ttm)0.23
PE Ratio24.09
Forward PE50.76
Dividendn/a
Ex-Dividend Daten/a
Volume1,763,417
Open5.59
Previous Close5.58
Day's Range5.58 - 5.59
52-Week Range3.11 - 5.59
Beta1.15
AnalystsBuy
Price Target6.07 (+8.6%)
Earnings DateMay 19, 2022

About ATRS

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheuma...

IndustryHealth Care Equipment & Supplies
IPO DateOct 2, 1996
CEORobert Apple
Employees201
Stock ExchangeNASDAQ
Ticker SymbolATRS
Full Company Profile

Financial Performance

In 2021, Antares Pharma's revenue was $183.98 million, an increase of 22.98% compared to the previous year's $149.60 million. Earnings were $46.29 million, a decrease of -17.64%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ATRS stock is "Buy." The 12-month stock price forecast is 6.07, which is an increase of 8.59% from the latest price.

Price Target
$6.07
(8.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, a...

Other symbols:HALO
1 week ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CMPI, PSB, ATRS, VWTR

NEW YORK , May 9, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of ...

Other symbols:CMPIPSBVWTR
1 week ago - PRNewsWire

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

SAN DIEGO , April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purc...

Other symbols:HALO
3 weeks ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Antares Pharma, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Antares Pharma, Inc. ("Antares") (NASDAQ: ATRS) regarding possible breaches of fiduciary duties and other v...

Other symbols:HALO
1 month ago - Newsfile Corp

Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?

Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increas...

1 month ago - Zacks Investment Research

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SRRA, ATRS, OBNK

NEW YORK , April 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Other symbols:OBNKSRRA
1 month ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Antares Pharma, Inc.

NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc. ("Antares" or the "...

Other symbols:HALO
1 month ago - PRNewsWire

Antares Pharma Inc shares up 45% on Wednesday: how come?

Antares Pharma Inc shares (NASDAQ: ATRS) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The ...

1 month ago - Invezz

Why Antares Pharma Stock Is Soaring Today

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Ant...

1 month ago - Benzinga

Why Is Antares Pharma (ATRS) Stock Up Today?

Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO). The post Why Is Antares Pharma (ATRS) Stock Up Today?

1 month ago - InvestorPlace

Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes

Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other symbols:AGRXKLDO
1 month ago - PennyStocks

Why Antares Pharma Stock Is Bolting Higher Today

The drug delivery specialist has reportedly agreed to a merger with Halozyme.

1 month ago - The Motley Fool

ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Antares Pharma, Inc. (NASDAQ: ATRS) to Halozyme Therapeutics, Inc. for $5.60 per share in c...

1 month ago - Business Wire

Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium

Shares of Antares Pharma Inc. ATRS, -0.27% rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeuti...

Other symbols:HALO
1 month ago - Market Watch

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business wit...

Other symbols:HALO
1 month ago - PRNewsWire

Antares Pharma's Oral Testosterone Treatment Scores FDA Approval

Antares Pharma Inc (NASDAQ: ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral trea...

1 month ago - Benzinga

Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates

Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results

Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million

2 months ago - GlobeNewsWire

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference

EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executiv...

2 months ago - GlobeNewsWire

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2...

3 months ago - GlobeNewsWire

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity

The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue.  The development program for ATRS-1902 supports a proposed indication of acute ...

4 months ago - Benzinga

Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue

EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”)...

4 months ago - GlobeNewsWire

Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources

EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior ...

4 months ago - GlobeNewsWire

Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue

EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-190...

4 months ago - GlobeNewsWire

MedMira strengthen its Board with New Appointment

HALIFAX, Nova Scotia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann to the board effective immediately.

5 months ago - GlobeNewsWire